Profile - To The Moon

785bfcf1

Posts · 89Posts · 89
Following · 0Following · 0
Followers · 0Followers · 0

- 785bfcf1785bfcf1
  ·2021-09-23
  $Ford(F)$reset position ?
  451 Comment
  1
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-22
  $Marin(MRIN)$7
  672 Comment
  1
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-22
  $NIO Inc.(NIO)$its time to enter
  342 Comment
  2
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-22
  $Marin(MRIN)$tought will be dropped once market open later, let's see. If not then I'll book the ticket too.
  1.05K 1
  Like
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-22
  Up up up
  Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
  Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently t
  Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
  560 Comment
  Like
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-21
  $Farmmi, Inc.(FAMI)$amazing, downtrend, low price but high volume.
  703 1
  1
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-19
  Like
  Ford wakes up badly burnt from its India dream
  NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s,
  Ford wakes up badly burnt from its India dream
  420 Comment
  Like
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-16
  $Camber Energy(CEI)$left pocket to right pocket... Just watching the show.
  419 Comment
  3
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-15
  Hmmm
  Wall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.
  The stock market hasn’t had a formal correction all year and many strategists are now calling for on
  Wall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.
  369 Comment
  5
  Share
  Report
- 785bfcf1785bfcf1
  ·2021-09-14
  Hmmmm
  Why SmileDirectClub Shares Surged Higher Today
  SmileDirectClub Inc (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's sessio
  Why SmileDirectClub Shares Surged Higher Today
  501 Comment
  Like
  Share
  Report
No followers yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3586474323146945","uuid":"3586474323146945","gmtCreate":1623383485295,"gmtModify":1627545406437,"name":"785bfcf1","pinyin":"785bfcf1","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":19,"headSize":57,"tweetSize":89,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-1","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Debut Tiger","description":"Join the tiger community for 500 days","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"80.01%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.94%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":863962623,"gmtCreate":1632353968962,"gmtModify":1676530759078,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>reset position ?","listText":"<a href=\"https://laohu8.com/S/F\">$Ford(F)$</a>reset position ?","text":"$Ford(F)$reset position ?","images":[{"img":"https://static.tigerbbs.com/52d069c1adf9568c246b758c73422a91","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863962623","isVote":1,"tweetType":1,"viewCount":451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":869760681,"gmtCreate":1632322353943,"gmtModify":1676530753055,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>7","listText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>7","text":"$Marin(MRIN)$7","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869760681","isVote":1,"tweetType":1,"viewCount":672,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869799156,"gmtCreate":1632320411675,"gmtModify":1676530752049,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>its time to enter","listText":"<a href=\"https://laohu8.com/S/NIO\">$NIO Inc.(NIO)$</a>its time to enter","text":"$NIO Inc.(NIO)$its time to enter","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869799156","isVote":1,"tweetType":1,"viewCount":342,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869540802,"gmtCreate":1632309107706,"gmtModify":1676530748491,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>tought will be dropped once market open later, let's see. If not then I'll book the ticket too.","listText":"<a href=\"https://laohu8.com/S/MRIN\">$Marin(MRIN)$</a>tought will be dropped once market open later, let's see. If not then I'll book the ticket too.","text":"$Marin(MRIN)$tought will be dropped once market open later, let's see. If not then I'll book the ticket too.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/869540802","isVote":1,"tweetType":1,"viewCount":1052,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":869505474,"gmtCreate":1632299727798,"gmtModify":1676530746477,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"Up up up","listText":"Up up up","text":"Up up up","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/869505474","repostId":"2169194634","repostType":2,"repost":{"id":"2169194634","pubTimestamp":1632246900,"share":"https://ttm.financial/m/news/2169194634?lang=&edition=fundamental","pubTime":"2021-09-22 01:55","market":"us","language":"en","title":"Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19","url":"https://stock-news.laohu8.com/highlight/detail?id=2169194634","media":"Business Wire","summary":"Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently t","content":"<html><body><ul>\n<li><i>Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently the cause of over 95 percent of new COVID-19 infections in the EU/EEA</i></li>\n<li><i>Participating EU/EEA countries can purchase bamlanivimab together with etesevimab directly from Lilly following national approval for emergency use or marketing authorization at the EU level</i></li>\n</ul>\n<p><b>VANCOUVER, British Columbia, September 21, 2021</b>--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. The agreement helps to provide access to treatments by enabling participating countries in the European Union (EU) and European Economic Area (EEA) to purchase the products directly from Lilly following national approval for emergency use or marketing authorization at the EU level.</p>\n<p>\"It is important that we use every tool available to combat COVID-19. With the rise of the highly contagious Delta variant, it is critical that patients who need it have access to antibody therapies that can neutralize the virus and prevent the progression to severe illness,\" said Carl Hansen, Ph.D., CEO and President of AbCellera.</p>\n<p>In the U.S., bamlanivimab alone and together with etesevimab have been used to treat more than 535,000 patients, potentially keeping more than 25,000 patients out of the hospital and saving more than 10,000 lives. The Emergency Use Authorization (EUA) for bamlanivimab together with etesevimab in the U.S. was recently expanded to include post-exposure prophylaxis to prevent COVID-19.</p>\n<p>Pseudovirus and authentic virus studies demonstrate that bamlanivimab and etesevimab together retain neutralization activity against variants currently in circulation in many countries, including Delta and Alpha. Based on the high transmissibility of the Delta variant, currently over 95 percent of new COVID-19 infections in the EU/EEA have been identified as being caused by the Delta variant.</p>\n<p><b>About AbCellera’s Response to COVID-19</b></p>\n<p>AbCellera initially mobilized its pandemic response platform against COVID-19 in March of 2020, resulting in the discovery of bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the U.S. Food and Drug Administration (FDA). Bamlanivimab alone and together with other antibodies has treated hundreds of thousands of patients, preventing COVID-19-related hospitalizations and death.</p>\n<p>AbCellera’s ongoing efforts to respond to the COVID-19 pandemic have identified thousands of unique anti-SARS-CoV-2 human antibodies. These include bamlanivimab, bebtelovimab, and other antibodies that are in various stages of testing by AbCellera and its partners.</p>\n<p>AbCellera’s pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.</p>\n<p><b>About Bamlanivimab</b></p>\n<p>Bamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera’s pandemic response platform, in partnership with the Vaccine Research Center (VRC) at the National Institutes for Allergy and Infectious Diseases (NIAID). Within <a href=\"https://laohu8.com/S/AONE.U\">one</a> week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies and was both the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America, and to receive Emergency Use Authorization (EUA) from the FDA. Bamlanivimab alone and/or administered with etesevimab are authorized under special use pathways in more than 22 countries. In the U.S., bamlanivimab is currently only authorized for emergency use with etesevimab.</p>\n<p>Results from a Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) were published in the <i>New England Journal of Medicine</i>. Results from a Phase 3 study of bamlanivimab in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) were published in the <i>Journal of American Medical Association</i>. A Phase 2 study assessing the efficacy and safety of bamlanivimab alone, and bamlanivimab with other neutralizing antibodies versus placebo for the treatment of symptomatic low-risk COVID-19 in the outpatient setting (BLAZE-4, NCT04634409) has completed enrollment.</p>\n<p><b>About <a href=\"https://laohu8.com/S/ABCL\">AbCellera Biologics</a> Inc.</b></p>\n<p>AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.</p>\n<p><b>AbCellera Forward-looking Statements</b></p>\n<p>This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.</p>\n<p>In some cases, you can identify forward-looking statements by the words \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"project,\" \"potential,\" \"continue,\" \"ongoing\" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under \"Risk Factors,\" \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.</p>\n<p>Source: AbCellera Biologics Inc.</p>\n<p><span>View source version on businesswire.com: </span><span>https://www.businesswire.com/news/home/20210921006004/en/</span></p>\n<p><b>Contacts</b></p>\n<p><b>Inquiries</b></p>\n<p><b>Media</b>: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774<br/><b>Business Development</b>: Neil Berkley; bd@abcellera.com, +1(604)559-9005<br/><b>Investor Relations:</b> Melanie Solomon; ir@abcellera.com, +1(778)729-9116</p></body></html>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-22 01:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/lilly-supply-eu-eea-220-175500241.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently the cause of over 95 percent of new COVID-19 infections in the EU/EEA\nParticipating EU/EEA countries ...</p>\n\n<a href=\"https://finance.yahoo.com/news/lilly-supply-eu-eea-220-175500241.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://s.yimg.com/uu/api/res/1.2/UzFalv_go1Sfe6fYobMVaQ--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/uu/api/res/1.2/lE5h6wPsvj.jqDHTIdvkbQ--~B/aD0zMzk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a2e58cf34a79b9f519b83d5ba5e534a4","relate_stocks":{"ABCL":"AbCellera Biologics"},"source_url":"https://finance.yahoo.com/news/lilly-supply-eu-eea-220-175500241.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2169194634","content_text":"Bamlanivimab and etesevimab administered together neutralize the Delta variant, which is currently the cause of over 95 percent of new COVID-19 infections in the EU/EEA\nParticipating EU/EEA countries can purchase bamlanivimab together with etesevimab directly from Lilly following national approval for emergency use or marketing authorization at the EU level\n\nVANCOUVER, British Columbia, September 21, 2021--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at increased risk of progressing to severe COVID-19. The agreement helps to provide access to treatments by enabling participating countries in the European Union (EU) and European Economic Area (EEA) to purchase the products directly from Lilly following national approval for emergency use or marketing authorization at the EU level.\n\"It is important that we use every tool available to combat COVID-19. With the rise of the highly contagious Delta variant, it is critical that patients who need it have access to antibody therapies that can neutralize the virus and prevent the progression to severe illness,\" said Carl Hansen, Ph.D., CEO and President of AbCellera.\nIn the U.S., bamlanivimab alone and together with etesevimab have been used to treat more than 535,000 patients, potentially keeping more than 25,000 patients out of the hospital and saving more than 10,000 lives. The Emergency Use Authorization (EUA) for bamlanivimab together with etesevimab in the U.S. was recently expanded to include post-exposure prophylaxis to prevent COVID-19.\nPseudovirus and authentic virus studies demonstrate that bamlanivimab and etesevimab together retain neutralization activity against variants currently in circulation in many countries, including Delta and Alpha. Based on the high transmissibility of the Delta variant, currently over 95 percent of new COVID-19 infections in the EU/EEA have been identified as being caused by the Delta variant.\nAbout AbCellera’s Response to COVID-19\nAbCellera initially mobilized its pandemic response platform against COVID-19 in March of 2020, resulting in the discovery of bamlanivimab, the first monoclonal antibody therapy for COVID-19 to reach human testing and to be authorized for emergency use by the U.S. Food and Drug Administration (FDA). Bamlanivimab alone and together with other antibodies has treated hundreds of thousands of patients, preventing COVID-19-related hospitalizations and death.\nAbCellera’s ongoing efforts to respond to the COVID-19 pandemic have identified thousands of unique anti-SARS-CoV-2 human antibodies. These include bamlanivimab, bebtelovimab, and other antibodies that are in various stages of testing by AbCellera and its partners.\nAbCellera’s pandemic response capabilities were developed over the past three years as part of the Defense Advanced Research Projects Agency (DARPA) Pandemic Prevention Platform (P3) program. The goal of the P3 program is to establish a robust technology platform for pandemic response capable of developing field-ready medical countermeasures within 60 days of isolation of an unknown viral pathogen.\nAbout Bamlanivimab\nBamlanivimab is a recombinant, neutralizing human IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab was developed from an antibody that was discovered from the blood of a recovered COVID-19 patient using AbCellera’s pandemic response platform, in partnership with the Vaccine Research Center (VRC) at the National Institutes for Allergy and Infectious Diseases (NIAID). Within one week of receiving the sample, AbCellera screened over five million antibody-producing cells to identify and isolate approximately 500 unique antibodies that bind to SARS-CoV-2, the virus that causes COVID-19. The binding antibodies were then tested by AbCellera, the VRC, and Lilly to find those most effective in neutralizing the virus. Bamlanivimab was selected as the lead candidate from this group of antibodies and was both the first therapeutic candidate specifically developed against SARS-CoV-2 to enter human clinical trials in North America, and to receive Emergency Use Authorization (EUA) from the FDA. Bamlanivimab alone and/or administered with etesevimab are authorized under special use pathways in more than 22 countries. In the U.S., bamlanivimab is currently only authorized for emergency use with etesevimab.\nResults from a Phase 2/3 study in people recently diagnosed with COVID-19 in the ambulatory setting (BLAZE-1, NCT04427501) were published in the New England Journal of Medicine. Results from a Phase 3 study of bamlanivimab in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) were published in the Journal of American Medical Association. A Phase 2 study assessing the efficacy and safety of bamlanivimab alone, and bamlanivimab with other neutralizing antibodies versus placebo for the treatment of symptomatic low-risk COVID-19 in the outpatient setting (BLAZE-4, NCT04634409) has completed enrollment.\nAbout AbCellera Biologics Inc.\nAbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.\nAbCellera Forward-looking Statements\nThis press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.\nIn some cases, you can identify forward-looking statements by the words \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"intend,\" \"plan,\" \"anticipate,\" \"believe,\" \"estimate,\" \"predict,\" \"project,\" \"potential,\" \"continue,\" \"ongoing\" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under \"Risk Factors,\" \"Management's Discussion and Analysis of Financial Condition and Results of Operations\" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.\nSource: AbCellera Biologics Inc.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210921006004/en/\nContacts\nInquiries\nMedia: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774Business Development: Neil Berkley; bd@abcellera.com, +1(604)559-9005Investor Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116","news_type":1},"isVote":1,"tweetType":1,"viewCount":560,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860509825,"gmtCreate":1632185759267,"gmtModify":1676530719999,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/FAMI\">$Farmmi, Inc.(FAMI)$</a>amazing, downtrend, low price but high volume.","listText":"<a href=\"https://laohu8.com/S/FAMI\">$Farmmi, Inc.(FAMI)$</a>amazing, downtrend, low price but high volume.","text":"$Farmmi, Inc.(FAMI)$amazing, downtrend, low price but high volume.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/860509825","isVote":1,"tweetType":1,"viewCount":703,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3581686650032769","authorId":"3581686650032769","name":"Mr凡凡","avatar":"https://static.tigerbbs.com/74f90b19678878f062e15d5a34dbdc36","crmLevel":1,"crmLevelSwitch":1,"idStr":"3581686650032769","authorIdStr":"3581686650032769"},"content":"One world , all gambler , come for quick money","text":"One world , all gambler , come for quick money","html":"One world , all gambler , come for quick money"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":887820372,"gmtCreate":1632018674796,"gmtModify":1676530687228,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/887820372","repostId":"2168264185","repostType":2,"repost":{"id":"2168264185","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1631865384,"share":"https://ttm.financial/m/news/2168264185?lang=&edition=fundamental","pubTime":"2021-09-17 15:56","market":"us","language":"en","title":"Ford wakes up badly burnt from its India dream","url":"https://stock-news.laohu8.com/highlight/detail?id=2168264185","media":"Reuters","summary":"NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s,","content":"<p>NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s, U.S. carmakers believed they were buying into a boom - the next China.</p>\n<p>The economy had been liberalised in 1991, the government was welcoming investors, and the middle class was expected to fuel a consumption frenzy. Rising disposable income would help foreign carmakers to a market share of as much as 10%, forecasters said.</p>\n<p>It never happened.</p>\n<p>Last week, Ford took a $2 billion hit&nbsp;to stop making cars in India, following compatriots General Motors Co and Harley-Davidson Inc in closing factories in the country.</p>\n<p>Among foreigners that remain, Japan's Nissan Motor Co Ltd&nbsp;and even Germany's <a href=\"https://laohu8.com/S/VLKAF\">Volkswagen AG</a>&nbsp;- the world's biggest automaker by sales - each hold less than 1% of a car market once forecast to be the third-largest by 2020, after China and the United States, with annual sales of 5 million.</p>\n<p>Instead, sales have stagnated at about 3 million cars. The growth rate has slowed to 3.6% in the last decade versus 12% a decade earlier.</p>\n<p>Ford's retreat marks the end of an Indian dream for U.S. carmakers. It also follows its exit from Brazil announced in January reflecting an industry pivot from emerging markets to what is now widely seen as make-or-break investment in electric vehicles.</p>\n<p>Analysts and executives said foreigners badly misjudged India's potential and underestimated the complexities of operating in a vast country that rewards domestic procurement.</p>\n<p>Many failed to adapt to a preference for small, cheap, fuel-efficient cars that could bump over uneven roads without needing expensive repairs. In India, 95% of cars are priced below $20,000.</p>\n<p>Lower tax on small cars also made it harder for makers of larger cars for Western markets to compete with small-car specialists such as Japan's Suzuki Motor Corp - controlling shareholder of <a href=\"https://laohu8.com/S/MRZUY\">Maruti Suzuki India Ltd</a> , India's biggest carmaker by sales.</p>\n<p>Of foreign carmakers that invested alone in India over the past 25 years, analysts said only South Korea's Hyundai Motor Co</p>\n<p>stands out as a success, mainly due to its wide portfolio of small cars and a grasp of what Indian buyers want.</p>\n<p>\"Companies invested on the fallacy that India would have great potential and the purchasing power of buyers would go up, but the government failed to create that kind of environment and infrastructure,\" said Ravi Bhatia, president for India at JATO Dynamics, a provider of market data for the auto industry.</p>\n<p><b>EARLY MISSTEP</b></p>\n<p>Some of Ford's missteps can be traced to when it drove into India in the mid-1990s alongside Hyundai. Whereas Hyundai entered with the small, affordable \"Santro\", Ford offered the \"Escort\" saloon, first launched in Europe in the 1960s.</p>\n<p>The Escort's price shocked Indians used to Maruti Suzuki's more affordable prices, said former Ford India executive Vinay Piparsania.</p>\n<p>Ford's narrow product range also made it hard to capitalise on the appeal won by its best-selling EcoSport and Endeavour sport utility vehicles (SUVs), said analyst Ammar Master at LMC.</p>\n<p>The carmaker said it had considered bringing more models to India but determined it could not do so profitably.</p>\n<p>\"The struggle for many global brands has always been meeting India's price point because they brought global products that were developed for mature markets at a high-cost structure,\" said Master.</p>\n<p>A peculiarity of the Indian market came in mid-2000 with a lower tax rate for cars measuring less than 4 metres (13.12 ft) in length. That left Ford and rivals building India-specific sub-4 metre saloons for which sales ultimately disappointed.</p>\n<p>\"U.S. manufacturers with large truck DNAs struggled to create a good and profitable small vehicle. Nobody got the product quite right and losses piled up,\" said JATO's Bhatia.</p>\n<p><b>RISE AND FALL</b></p>\n<p>Ford had excess capacity at its first India plant when it invested $1 billion on a second in 2015. It had planned to make India an export base and raise its share of a market projected to hit 7 million cars a year by 2020 and 9 million by 2025.</p>\n<p>But the sales never followed and overall market growth stalled. Ford now utilises only about 20% of its combined annual capacity of 440,000 cars.</p>\n<p>To use its excess capacity, Ford planned to build compact cars in India for emerging markets but shelved plans</p>\n<p>in 2016 amid a global consumer preference shift to SUVs.</p>\n<p>It changed its cost structure in 2018 and the following year started work on a joint venture with local peer Mahindra &amp; Mahindra Ltd</p>\n<p>designed to reduce costs. Three years later, in December, the partners abandoned the idea</p>\n<p>After sinking $2.5 billion in India since entry and burning another $2 billion over the past decade alone, Ford decided not to invest more.</p>\n<p>\"To continue investing ... we needed to show a path for a reasonable return on investment,\" Ford India head Anurag Mehrotra told reporters last week.</p>\n<p>\"Unfortunately, we are not able to do that.\"</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ford wakes up badly burnt from its India dream</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFord wakes up badly burnt from its India dream\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-09-17 15:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s, U.S. carmakers believed they were buying into a boom - the next China.</p>\n<p>The economy had been liberalised in 1991, the government was welcoming investors, and the middle class was expected to fuel a consumption frenzy. Rising disposable income would help foreign carmakers to a market share of as much as 10%, forecasters said.</p>\n<p>It never happened.</p>\n<p>Last week, Ford took a $2 billion hit&nbsp;to stop making cars in India, following compatriots General Motors Co and Harley-Davidson Inc in closing factories in the country.</p>\n<p>Among foreigners that remain, Japan's Nissan Motor Co Ltd&nbsp;and even Germany's <a href=\"https://laohu8.com/S/VLKAF\">Volkswagen AG</a>&nbsp;- the world's biggest automaker by sales - each hold less than 1% of a car market once forecast to be the third-largest by 2020, after China and the United States, with annual sales of 5 million.</p>\n<p>Instead, sales have stagnated at about 3 million cars. The growth rate has slowed to 3.6% in the last decade versus 12% a decade earlier.</p>\n<p>Ford's retreat marks the end of an Indian dream for U.S. carmakers. It also follows its exit from Brazil announced in January reflecting an industry pivot from emerging markets to what is now widely seen as make-or-break investment in electric vehicles.</p>\n<p>Analysts and executives said foreigners badly misjudged India's potential and underestimated the complexities of operating in a vast country that rewards domestic procurement.</p>\n<p>Many failed to adapt to a preference for small, cheap, fuel-efficient cars that could bump over uneven roads without needing expensive repairs. In India, 95% of cars are priced below $20,000.</p>\n<p>Lower tax on small cars also made it harder for makers of larger cars for Western markets to compete with small-car specialists such as Japan's Suzuki Motor Corp - controlling shareholder of <a href=\"https://laohu8.com/S/MRZUY\">Maruti Suzuki India Ltd</a> , India's biggest carmaker by sales.</p>\n<p>Of foreign carmakers that invested alone in India over the past 25 years, analysts said only South Korea's Hyundai Motor Co</p>\n<p>stands out as a success, mainly due to its wide portfolio of small cars and a grasp of what Indian buyers want.</p>\n<p>\"Companies invested on the fallacy that India would have great potential and the purchasing power of buyers would go up, but the government failed to create that kind of environment and infrastructure,\" said Ravi Bhatia, president for India at JATO Dynamics, a provider of market data for the auto industry.</p>\n<p><b>EARLY MISSTEP</b></p>\n<p>Some of Ford's missteps can be traced to when it drove into India in the mid-1990s alongside Hyundai. Whereas Hyundai entered with the small, affordable \"Santro\", Ford offered the \"Escort\" saloon, first launched in Europe in the 1960s.</p>\n<p>The Escort's price shocked Indians used to Maruti Suzuki's more affordable prices, said former Ford India executive Vinay Piparsania.</p>\n<p>Ford's narrow product range also made it hard to capitalise on the appeal won by its best-selling EcoSport and Endeavour sport utility vehicles (SUVs), said analyst Ammar Master at LMC.</p>\n<p>The carmaker said it had considered bringing more models to India but determined it could not do so profitably.</p>\n<p>\"The struggle for many global brands has always been meeting India's price point because they brought global products that were developed for mature markets at a high-cost structure,\" said Master.</p>\n<p>A peculiarity of the Indian market came in mid-2000 with a lower tax rate for cars measuring less than 4 metres (13.12 ft) in length. That left Ford and rivals building India-specific sub-4 metre saloons for which sales ultimately disappointed.</p>\n<p>\"U.S. manufacturers with large truck DNAs struggled to create a good and profitable small vehicle. Nobody got the product quite right and losses piled up,\" said JATO's Bhatia.</p>\n<p><b>RISE AND FALL</b></p>\n<p>Ford had excess capacity at its first India plant when it invested $1 billion on a second in 2015. It had planned to make India an export base and raise its share of a market projected to hit 7 million cars a year by 2020 and 9 million by 2025.</p>\n<p>But the sales never followed and overall market growth stalled. Ford now utilises only about 20% of its combined annual capacity of 440,000 cars.</p>\n<p>To use its excess capacity, Ford planned to build compact cars in India for emerging markets but shelved plans</p>\n<p>in 2016 amid a global consumer preference shift to SUVs.</p>\n<p>It changed its cost structure in 2018 and the following year started work on a joint venture with local peer Mahindra &amp; Mahindra Ltd</p>\n<p>designed to reduce costs. Three years later, in December, the partners abandoned the idea</p>\n<p>After sinking $2.5 billion in India since entry and burning another $2 billion over the past decade alone, Ford decided not to invest more.</p>\n<p>\"To continue investing ... we needed to show a path for a reasonable return on investment,\" Ford India head Anurag Mehrotra told reporters last week.</p>\n<p>\"Unfortunately, we are not able to do that.\"</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"F":"福特汽车"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2168264185","content_text":"NEW DELHI, Sept 17 (Reuters) - When Ford Motor Co built its first factory in India in the mid-1990s, U.S. carmakers believed they were buying into a boom - the next China.\nThe economy had been liberalised in 1991, the government was welcoming investors, and the middle class was expected to fuel a consumption frenzy. Rising disposable income would help foreign carmakers to a market share of as much as 10%, forecasters said.\nIt never happened.\nLast week, Ford took a $2 billion hit to stop making cars in India, following compatriots General Motors Co and Harley-Davidson Inc in closing factories in the country.\nAmong foreigners that remain, Japan's Nissan Motor Co Ltd and even Germany's Volkswagen AG - the world's biggest automaker by sales - each hold less than 1% of a car market once forecast to be the third-largest by 2020, after China and the United States, with annual sales of 5 million.\nInstead, sales have stagnated at about 3 million cars. The growth rate has slowed to 3.6% in the last decade versus 12% a decade earlier.\nFord's retreat marks the end of an Indian dream for U.S. carmakers. It also follows its exit from Brazil announced in January reflecting an industry pivot from emerging markets to what is now widely seen as make-or-break investment in electric vehicles.\nAnalysts and executives said foreigners badly misjudged India's potential and underestimated the complexities of operating in a vast country that rewards domestic procurement.\nMany failed to adapt to a preference for small, cheap, fuel-efficient cars that could bump over uneven roads without needing expensive repairs. In India, 95% of cars are priced below $20,000.\nLower tax on small cars also made it harder for makers of larger cars for Western markets to compete with small-car specialists such as Japan's Suzuki Motor Corp - controlling shareholder of Maruti Suzuki India Ltd , India's biggest carmaker by sales.\nOf foreign carmakers that invested alone in India over the past 25 years, analysts said only South Korea's Hyundai Motor Co\nstands out as a success, mainly due to its wide portfolio of small cars and a grasp of what Indian buyers want.\n\"Companies invested on the fallacy that India would have great potential and the purchasing power of buyers would go up, but the government failed to create that kind of environment and infrastructure,\" said Ravi Bhatia, president for India at JATO Dynamics, a provider of market data for the auto industry.\nEARLY MISSTEP\nSome of Ford's missteps can be traced to when it drove into India in the mid-1990s alongside Hyundai. Whereas Hyundai entered with the small, affordable \"Santro\", Ford offered the \"Escort\" saloon, first launched in Europe in the 1960s.\nThe Escort's price shocked Indians used to Maruti Suzuki's more affordable prices, said former Ford India executive Vinay Piparsania.\nFord's narrow product range also made it hard to capitalise on the appeal won by its best-selling EcoSport and Endeavour sport utility vehicles (SUVs), said analyst Ammar Master at LMC.\nThe carmaker said it had considered bringing more models to India but determined it could not do so profitably.\n\"The struggle for many global brands has always been meeting India's price point because they brought global products that were developed for mature markets at a high-cost structure,\" said Master.\nA peculiarity of the Indian market came in mid-2000 with a lower tax rate for cars measuring less than 4 metres (13.12 ft) in length. That left Ford and rivals building India-specific sub-4 metre saloons for which sales ultimately disappointed.\n\"U.S. manufacturers with large truck DNAs struggled to create a good and profitable small vehicle. Nobody got the product quite right and losses piled up,\" said JATO's Bhatia.\nRISE AND FALL\nFord had excess capacity at its first India plant when it invested $1 billion on a second in 2015. It had planned to make India an export base and raise its share of a market projected to hit 7 million cars a year by 2020 and 9 million by 2025.\nBut the sales never followed and overall market growth stalled. Ford now utilises only about 20% of its combined annual capacity of 440,000 cars.\nTo use its excess capacity, Ford planned to build compact cars in India for emerging markets but shelved plans\nin 2016 amid a global consumer preference shift to SUVs.\nIt changed its cost structure in 2018 and the following year started work on a joint venture with local peer Mahindra & Mahindra Ltd\ndesigned to reduce costs. Three years later, in December, the partners abandoned the idea\nAfter sinking $2.5 billion in India since entry and burning another $2 billion over the past decade alone, Ford decided not to invest more.\n\"To continue investing ... we needed to show a path for a reasonable return on investment,\" Ford India head Anurag Mehrotra told reporters last week.\n\"Unfortunately, we are not able to do that.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":420,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885587411,"gmtCreate":1631803637033,"gmtModify":1676530640895,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/CEI\">$Camber Energy(CEI)$</a>left pocket to right pocket... Just watching the show.","listText":"<a href=\"https://laohu8.com/S/CEI\">$Camber Energy(CEI)$</a>left pocket to right pocket... Just watching the show.","text":"$Camber Energy(CEI)$left pocket to right pocket... Just watching the show.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/885587411","isVote":1,"tweetType":1,"viewCount":419,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882591370,"gmtCreate":1631703883590,"gmtModify":1676530613091,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"Hmmm","listText":"Hmmm","text":"Hmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882591370","repostId":"1133293397","repostType":4,"repost":{"id":"1133293397","pubTimestamp":1631691783,"share":"https://ttm.financial/m/news/1133293397?lang=&edition=fundamental","pubTime":"2021-09-15 15:43","market":"us","language":"en","title":"Wall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.","url":"https://stock-news.laohu8.com/highlight/detail?id=1133293397","media":"Barrons","summary":"The stock market hasn’t had a formal correction all year and many strategists are now calling for on","content":"<p>The stock market hasn’t had a formal correction all year and many strategists are now calling for one. One bank still sees gains ahead because companies’ earnings are too good to ignore, but the rally it has penciled in would be far from spectacular.</p>\n<p>Several strategists are now looking for a negative return on the S&amp;P 500 by the end of the year. Some are calling for a correction, defined as a drawdown of at least 10%. The largest decline in the market benchmark so far this year was just 5%.</p>\n<p>Several factors, including valuations, could trigger the drop. The average stock on the&nbsp;S&amp;P 500&nbsp;currently trades at just under 21 times the earnings per share expected for the next 12 months. That is more than 35% higher than the long-term average.</p>\n<p>Falling bond yields, which make future profits worth more in current terms, have lifted valuations. But with the yield on 10-year Treasury debt currently at 1.31%— well below long-term inflation expectations of above 2%, a rare occurrence in the bond market—the decline could easily be over.Morgan Stanley‘s chief U.S. equity strategist, Mike Wilson, sees the 10-year yield hitting 1.8% by year-end, and the S&amp;P 500’s earnings multiple falling to 19 times.</p>\n<p>Even assuming corporate earnings are unaffected, this would mean severe downside for stocks. Wilson’s call on the level of the S&amp;P 500 relative to the aggregate per-share earnings of the companies included would bring the index down 9%.</p>\n<p>Stifel’s head of institutional equity strategy, Barry Bannister, said in a recent research note that lower earnings multiples resulting from higher bond yields could mean the S&amp;P 500 could fall 10% to 15%.</p>\n<p>Profits are another potential trouble spot, not least because of supply-chain issues. Already, several companies have lowered their forecasts for sales and earnings for the current quarter because problems getting parts are lowering their customers’—and their own—production. Analysts and management teams expect strong demand to lift profits when the supply problems ease and inventory levels climb again, but it isn’t clear when that might happen, or how bad the shortages of parts and finished goods could become.</p>\n<p>“This [supply constraints] will be a more substantial risk to the rally we’ll need to watch for,” wrote Tom Essaye, founder of Sevens Report Research. Prolonged trouble could mean unexpectedly severe damage to profits.</p>\n<p>Higher corporate taxes would also bring earnings down, but stock prices don’t seem to be reflecting that risk.Goldman Sachs&nbsp;strategists said earlier this year that S&amp;P 500 EPS could fall 5% if the corporate tax rate rises to 25% from 21% — and House Democrats proposed an increase to 26.5% on Monday.</p>\n<p>Still, RBC strategists raised their S&amp;P 500 price target to 4,500 on Monday. They now see S&amp;P 500 earnings per share for 2022 coming in at $222, only slightly above the consensus call of $218 among analysts. While RBC acknowledges the average multiple may fall to just above 20 times, its call implies a gain of just 0.7% relative to Monday’s closing level.</p>\n<p>Even the more bullish observers aren’t forecasting anything exciting for stocks.</p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Wall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWall Street Expects the S&P 500 to Fall. Even the Optimists Aren't Very Upbeat.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-15 15:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.barrons.com/articles/s-p-500-correction-outlook-strategists-51631632149?mod=hp_LATEST><strong>Barrons</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The stock market hasn’t had a formal correction all year and many strategists are now calling for one. One bank still sees gains ahead because companies’ earnings are too good to ignore, but the rally...</p>\n\n<a href=\"https://www.barrons.com/articles/s-p-500-correction-outlook-strategists-51631632149?mod=hp_LATEST\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index"},"source_url":"https://www.barrons.com/articles/s-p-500-correction-outlook-strategists-51631632149?mod=hp_LATEST","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1133293397","content_text":"The stock market hasn’t had a formal correction all year and many strategists are now calling for one. One bank still sees gains ahead because companies’ earnings are too good to ignore, but the rally it has penciled in would be far from spectacular.\nSeveral strategists are now looking for a negative return on the S&P 500 by the end of the year. Some are calling for a correction, defined as a drawdown of at least 10%. The largest decline in the market benchmark so far this year was just 5%.\nSeveral factors, including valuations, could trigger the drop. The average stock on the S&P 500 currently trades at just under 21 times the earnings per share expected for the next 12 months. That is more than 35% higher than the long-term average.\nFalling bond yields, which make future profits worth more in current terms, have lifted valuations. But with the yield on 10-year Treasury debt currently at 1.31%— well below long-term inflation expectations of above 2%, a rare occurrence in the bond market—the decline could easily be over.Morgan Stanley‘s chief U.S. equity strategist, Mike Wilson, sees the 10-year yield hitting 1.8% by year-end, and the S&P 500’s earnings multiple falling to 19 times.\nEven assuming corporate earnings are unaffected, this would mean severe downside for stocks. Wilson’s call on the level of the S&P 500 relative to the aggregate per-share earnings of the companies included would bring the index down 9%.\nStifel’s head of institutional equity strategy, Barry Bannister, said in a recent research note that lower earnings multiples resulting from higher bond yields could mean the S&P 500 could fall 10% to 15%.\nProfits are another potential trouble spot, not least because of supply-chain issues. Already, several companies have lowered their forecasts for sales and earnings for the current quarter because problems getting parts are lowering their customers’—and their own—production. Analysts and management teams expect strong demand to lift profits when the supply problems ease and inventory levels climb again, but it isn’t clear when that might happen, or how bad the shortages of parts and finished goods could become.\n“This [supply constraints] will be a more substantial risk to the rally we’ll need to watch for,” wrote Tom Essaye, founder of Sevens Report Research. Prolonged trouble could mean unexpectedly severe damage to profits.\nHigher corporate taxes would also bring earnings down, but stock prices don’t seem to be reflecting that risk.Goldman Sachs strategists said earlier this year that S&P 500 EPS could fall 5% if the corporate tax rate rises to 25% from 21% — and House Democrats proposed an increase to 26.5% on Monday.\nStill, RBC strategists raised their S&P 500 price target to 4,500 on Monday. They now see S&P 500 earnings per share for 2022 coming in at $222, only slightly above the consensus call of $218 among analysts. While RBC acknowledges the average multiple may fall to just above 20 times, its call implies a gain of just 0.7% relative to Monday’s closing level.\nEven the more bullish observers aren’t forecasting anything exciting for stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":369,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886588272,"gmtCreate":1631605657996,"gmtModify":1676530587936,"author":{"id":"3586474323146945","authorId":"3586474323146945","name":"785bfcf1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586474323146945","authorIdStr":"3586474323146945"},"themes":[],"htmlText":"Hmmmm","listText":"Hmmmm","text":"Hmmmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/886588272","repostId":"2167044533","repostType":2,"repost":{"id":"2167044533","pubTimestamp":1631575849,"share":"https://ttm.financial/m/news/2167044533?lang=&edition=fundamental","pubTime":"2021-09-14 07:30","market":"us","language":"en","title":"Why SmileDirectClub Shares Surged Higher Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2167044533","media":"Benzinga","summary":"SmileDirectClub Inc (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's sessio","content":"<p><b>SmileDirectClub Inc</b> (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's session as&nbsp;traders on social media circulate the stock, highlighting its high short interest.</p>\n<p>The average session&nbsp;volume is about 6.5 million. The daily trading&nbsp;volume for Monday's session was over 42 million.</p>\n<p>SmileDirectClub was <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the top three trending stocks on Stocktwits at publication time.</p>\n<p>The percentage of the float sold short is about 33%, according to data from&nbsp;Benzinga Pro.</p>\n<p>SmileDirectClub&nbsp;is engaged in the orthodontics business. It is mainly involved in the sale of aligners, impression kits, whitening gel&nbsp;and retainers.</p>\n<p><b>SDC Price Action:</b> SmileDirectClub has traded as high as $16.07 and as low as $4.63 over a 52-week period.</p>\n<p>The stock closed up 16.12% at $5.98 on Monday.</p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why SmileDirectClub Shares Surged Higher Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy SmileDirectClub Shares Surged Higher Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-14 07:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/why-smiledirectclub-shares-surged-higher-201349699.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SmileDirectClub Inc (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's session as traders on social media circulate the stock, highlighting its high short interest.\nThe average ...</p>\n\n<a href=\"https://finance.yahoo.com/news/why-smiledirectclub-shares-surged-higher-201349699.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SDC":"SmileDirectClub, Inc."},"source_url":"https://finance.yahoo.com/news/why-smiledirectclub-shares-surged-higher-201349699.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2167044533","content_text":"SmileDirectClub Inc (NASDAQ: SDC) is trading higher on abnormally high volume during Monday's session as traders on social media circulate the stock, highlighting its high short interest.\nThe average session volume is about 6.5 million. The daily trading volume for Monday's session was over 42 million.\nSmileDirectClub was one of the top three trending stocks on Stocktwits at publication time.\nThe percentage of the float sold short is about 33%, according to data from Benzinga Pro.\nSmileDirectClub is engaged in the orthodontics business. It is mainly involved in the sale of aligners, impression kits, whitening gel and retainers.\nSDC Price Action: SmileDirectClub has traded as high as $16.07 and as low as $4.63 over a 52-week period.\nThe stock closed up 16.12% at $5.98 on Monday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":501,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":true}